EGFR-TKI resistance in NSCLC patients: mechanisms and strategies - Test2 - elhamkhani - TriplyDB

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

http://www.wikidata.org/entity/Q28394310

about

The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis Regulation of voltage-gated potassium channels attenuates resistance of side-population cells to gefitinib in the human lung cancer cell line NCI-H460 Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met Sarcomatous transformation of EGFR and TP53 mutation-positive metastatic adenocarcinoma of the lungs, masquerading as a primary pleomorphic sarcoma of the proximal femur.The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.Curative effect analysis of different treatments for gefitinib-resistance advanced non-small cell lung cancer patients.Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response.Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma.Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation.Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.MicroRNA and MET in lung cancer.The enhanced tumor inhibitory effects of gefitinib and L-ascorbic acid combination therapy in non-small cell lung cancer cells.Fisetin, a dietary phytochemical, overcomes Erlotinib-resistance of lung adenocarcinoma cells through inhibition of MAPK and AKT pathways.Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer.Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report.Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question?Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.A comparison of QuantStudio™ 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients.Advances in studies of tyrosine kinase inhibitors and their acquired resistance.Targeting tumour microenvironment by tyrosine kinase inhibitor.Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients.Role of long non-coding RNA in drug resistance in non-small cell lung cancer.[Advances in Association of Estrogen and Human Non-small Cell Lung Cancer].The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting /CASP1 axis

P2860

Q26765247-D52F6497-E03E-4C03-BB15-264D52C1C783 Q26781662-85CD8A1B-896E-41BB-99A1-DB26ACAB227E Q26798147-D48B8D3F-2EA0-4DA0-85AE-F551A718C07B Q28066130-7094273A-1D2C-4E77-B80E-26991D7EF2CB Q32181933-95515BE2-9F5B-4BDA-9DEC-55CD156502BD Q33677872-580689F9-B925-4625-B0D7-EECA251F0227 Q33774131-CD92916D-A993-4D66-AEF4-D89DEFD682B8 Q35632411-7BC3FE57-5C22-46F8-BB39-E58A3A96AE0A Q35740819-41E8780D-32CB-48C2-8CF9-A03A7F4F2A15 Q35807946-1BBF608E-3705-458D-B5BE-AB4FEAB50C19 Q36247353-C42C287D-9F47-4D00-9905-15F94D28E218 Q36317821-EF386B9E-BB24-498A-B049-4DC16671D9A0 Q36414519-2AEB9666-93DE-4BB8-A279-D833336BE09D Q36821248-43F63850-C81A-4051-887B-723690B80BD4 Q37330932-6397355B-EF01-4C71-8C9F-430C06467E56 Q37482664-81D89FC1-4EB3-45CE-97F4-CAE6DEF7A9F4 Q37688567-EA4DBCDC-15A9-42E6-B792-779654D0C25A Q37698613-435B4AC0-CE45-44A6-96FF-04DCE44EA66B Q38493279-4E79A0BF-95B4-4385-ADCE-89332A059FA4 Q38697702-3948BAE0-E19F-4DBA-978D-4DBC583212FF Q38728165-1B9B5FB7-E80A-49C0-BD3B-18841E3795C8 Q39254692-2F334611-C6C2-4AC3-9EE2-C57042C740C8 Q40979412-C7C5FFD8-C08E-4310-BAF3-FDFF1FF940DB Q42106824-1349B289-1127-4C9D-931E-220D95906D67 Q42697768-90121A91-DC34-494A-B95A-E791ED9BA24B Q44658595-4652FA72-AAD2-4812-B169-60F25C0EC27C Q45215365-171CEC91-6731-49E6-AB2E-ACA38651E74B Q48500283-36BEACC5-2C65-4646-85A7-DE476375203E Q49887903-52F6CB38-93A0-42E3-8E30-37BE38E62A76 Q49887906-77C2F3E8-FE50-4F1A-9D78-4050E913CBB7 Q52602513-A21EBB37-FFFC-4E16-BF50-1E0AE79FFD50 Q52803546-BE10E3DA-D9B9-40BA-85B3-F6DE937430DB Q53687949-77AC20EE-878F-41E1-B3EB-A6297890F5F2 Q53843124-6B989A8F-8504-441C-849B-34F259F36625 Q58568397-43529F46-7019-4C89-A319-69ED669D90E6 Q58693580-EAC9E316-8929-460F-8CB5-D2600E41FBEE

P2860

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

http://www.wikidata.org/entity/Q28394310

description

2014 nî lūn-bûn

@nan

2014 թուականին հրատարակուած գիտական յօդուած

@hyw

2014 թվականին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

@ast

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

@en

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

@nl

type

label

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

@ast

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

@en

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

@nl

prefLabel

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

@ast

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

@en

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

@nl

P1476

Q28394310-EDE2ED1C-ECD8-4BB5-9C4D-7971A5C73E3C

P2093

Q28394310-14CD8FCA-59A7-4CE5-93E2-0203889A4F60

Q28394310-4A06DED8-326C-4BA6-A162-F07FEB168FA9

Q28394310-6205330F-33B9-420A-B2D9-4C13DBAFB639

P2860

Q28394310-00256D6D-2ACA-4EDD-9B5B-F820C4F9B5EA

Q28394310-008C484A-5E05-435E-8EDF-9CEC708E83D5

Q28394310-03A3C11A-F877-421C-8B07-D431B816A4B5

Q28394310-04252374-6C4E-40FF-98F7-C13D85517AFF

Q28394310-045CA6E0-CBE9-4B07-91D1-3753FBF184DD

Q28394310-056E39E1-AB51-4EE6-BC71-F68030AC8726

Q28394310-05823C91-5E6E-4FF1-A5E3-86E5E17F2229

Q28394310-073ACF64-CFB3-40E3-9653-BDD157006A1F

Q28394310-0807A70D-4D1C-4BF6-8620-00EF15175BCA

Q28394310-10B1BF8D-C04C-4A21-A464-7D2B51086510

P304

Q28394310-85874EE3-CF24-484E-9A61-2EF01E9E8459

P31

Q28394310-000239F5-B9ED-4BBA-83D0-3AC09142F88A

Q28394310-ab38141b-ee47-4ba4-9c75-d04c303d67a3

P3181

Q28394310-85DECDF3-6E2A-430D-846B-A1A834C6F6B9

P407

Q28394310-D4D54A46-C643-461D-AAAE-CF6CCC535936

P433

Q28394310-1365DAA7-8496-4841-9974-234D11465189

P478

Q28394310-76C69598-C88D-4059-AD3A-7BCA840D8A2B

P577

Q28394310-23CF4257-AF6B-4A85-B9AD-C3A83B515EF2

P698

Q28394310-80ED8C4D-4E46-45D8-A5B0-3168A1F8DA6F

P921

Q28394310-1505479A-6BA3-4CFF-9004-E978EE16C622

P932

Q28394310-321F8FF4-2D69-4100-8AF0-4D561E62DC1C

P3181

P1476

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

@en

P2093

Hongchuan Jin

http://www.w3.org/2001/XMLSchema#string

Xian Wang

http://www.w3.org/2001/XMLSchema#string

Yuxin Lin

http://www.w3.org/2001/XMLSchema#string

P2860

The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Targeting the PI3K signaling pathway in cancer

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells

P304

411-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3275618

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25232485

http://www.w3.org/2001/XMLSchema#string

P921

P932

4163608

http://www.w3.org/2001/XMLSchema#string